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Abstract  27 
Background: Up-regulation of kallikreins (KLK) including KLK5 has been reported in atopic 28 
dermatitis (AD). KLK5 has biological functions which include degrading desmosomal proteins and 29 
inducing pro-inflammatory cytokine secretion through protease activated receptor 2 (PAR2). 30 
However, due to the complex interactions between various cells in AD inflamed skin, it is difficult 31 
to dissect the precise and multiple roles of up-regulated KLK5 in AD skin. 32 
Objective:  We investigated the effect of up-regulated KLK5 on the expression of epidermal related 33 
proteins and cytokines in keratinocytes and on skin architecture. 34 
Methods: Lesional and non-lesional AD skin biopsies were collected for analysis of morphology 35 
and protein expression. The relationship between KLK5 and barrier related molecules was 36 
investigated using an ex-vivo dermatitis skin model with transient KLK5 expression and a cell 37 
model with persistent KLK5 expression. The influence of up-regulated KLK5 on epidermal 38 
morphology was investigated using an in vivo skin graft model.  39 
Results: Up-regulation of KLK5 and abnormal expression of desmoglein 1 (DSG1) and filaggrin 40 
(FLG), but not PAR2 were identified in AD skin. PAR2 was increased in response to transient up-41 
regulation of KLK5, while persistently up-regulated KLK5 did not show this effect. Persistently up-42 
regulated KLK5 degraded DSG1 and stimulated secretion of IL-8, IL-10 and TSLP independent of 43 
PAR2 activity. With control of higher KLK5 activity by the inhibitor SFTI-G, restoration of DSG1 44 
expression and a reduction in AD-related cytokine IL-8, TLSP and IL-10 secretion were observed. 45 
Furthermore, persistently elevated KLK5 could induce AD-like skin architecture in an in vivo skin 46 
graft model. .  47 
Conclusion: Persistently up-regulated KLK5 resulted in AD-like skin architecture and secretion of 48 
AD-related cytokines from keratinocytes in a PAR-2 independent manner. Inhibition of KLK5-49 
mediated effects may offer potential as a therapeutic approach in AD.  50 
 51 
 52 
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Key messages  53 
• Persistently up-regulated KLK5 induces PAR2-independent IL-8, IL10 and TSLP secretion, 54 
causing abnormal keratinocyte growth and AD-like skin architecture.  55 
• Inhibition of KLK5-mediated effects restored DSG1 expression and decreased AD-related 56 
cytokine expression, thus suggesting that KLK5 inhibition may be useful as a potential 57 
treatment for AD. 58 
 59 
Capsule summary  60 
Persistently increased serine protease kallikrein 5 modifies skin barrier proteins, upregulates AD-61 
related cytokine expression and induces AD-like skin architecture.  Inhibition of KLK5 may offer 62 
potential as a treatment strategy in AD.  63 
 64 
Key word  65 
Kallikrein 5, atopic dermatitis, skin barrier, serine protease inhibitor, SFTI 66 
 67 
abbreviations 68 
KLK5 (kallikrein), DSG1 (desmoglein 1), PAR2 (protease activated receptor 2), CAP18 69 
(cathelicidin precursor cationic antimicrobial protein 18), AD (atopic dermatitis), NS (Netherton 70 
syndrome), FLG (filaggrin), UT (untransduced keratinocytes), AP (PAR2 agonist), TSLP (thymic 71 
stromal lymphopoietin), rKLK5 (recombinant KLK5). 72 
 73 
 74 
 75 
 76 
 77 
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Introduction 78 
Tissue kallikreins (KLKs) are a family of fifteen (chymo)trypsin-like serine proteases which 79 
function through proteolytic cascades in the skin. Eight KLKs are expressed in the skin with KLK5 80 
being one of the three most important, the others being KLK7 and KLK141. KLK5 is produced as 81 
an inactive precursor from keratinocytes and activated by matriptase and KLK142,3, but can also 82 
undergo self-activation. It is able to activate other KLKs, therefore, KLK5 has been considered to 83 
be the initiator of KLK activation cascades within the skin4.  84 
KLK5 is expressed in the outmost layers of the epidermis, and the importance of its biological 85 
function in the epidermal barrier was initially discovered through studies on Netherton Syndrome 86 
(NS), a rare severe autosomal recessive skin disorder caused by mutations in the SPINK5 gene4,5. In 87 
NS, SPINK5 mutations cause loss of function of its encoded protein LEKTI, a multi-domain serine 88 
protease inhibitor, leading to elevated activity of KLK5. This results in cleavage of intercellular 89 
adhesion protein desmoglein 1 (DSG1), causing excessive desquamation of corneocytes and leading 90 
to a severely defective skin barrier, a major cause of early neonatal death in NS6. In addition to its 91 
involvement in DSG1 degradation, KLK5 is able to activate protease activated receptor 2 (PAR2), a 92 
subfamily of G protein-coupled receptors, and trigger expression of pro-inflammatory cytokines 93 
such as IL-87,8. KLK5 is also involved in the innate immune system within the skin by cleaving the 94 
cathelicidin precursor cationic antimicrobial protein 18 (CAP18) at its c-terminus to produce 37 95 
amino acid peptide LL-37, a major antimicrobial peptide with broad-spectrum antimicrobial 96 
activity9.  97 
Up-regulation of kallikreins including KLK5 has been reported in many chronic inflammatory skin 98 
diseases including atopic dermatitis (AD)10,11. AD is a multifactorial disease caused by complex 99 
interactions between genetic and environmental factors, with evidence that irritants (such as those 100 
contained in soaps) can further damage the skin barrier and exacerbate the inflammation in AD 101 
patients12. In the past decade, significant progress has been made in the area of molecular genetics 102 
with identification of several genes linked to AD including SPINK5, KLK7 and FLG13-15. These 103 
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findings have led to the proposition that an impaired epidermal barrier is the primary event, 104 
allowing percutaneous allergen penetration and causing an enhanced Th2-skewed immune-105 
response16. The induced inflammatory response further compromises barrier function, resulting in 106 
abnormal expression, activity and assembly of skin barrier related proteins, enzymes and lipids. 107 
Aberrant up-regulation of KLK5 in AD skin has been reported10,11 and increased KLK5 may play a 108 
key role in the pathogenesis of the dysfunctional skin. However, due to the complex interactions 109 
between various cells in AD inflamed skin, it is difficult to dissect the exact role of up-regulated 110 
KLK5 in AD skin.  111 
In this study, we confirmed up-regulation of KLK5 and abnormal expression of KLK5 down-stream 112 
molecules DSG1 and filaggrin (FLG), but not PAR2 in AD skin. We also identified significantly 113 
increased KLK5 and PAR2 expressions in an ex-vivo dermatitis model, but not in the cell model 114 
with persistent over-expression of KLK5, illustrating different responses of PAR2 to transient or 115 
persistent KLK5 stimulation. We also demonstrated that increased IL-8, IL-10 and TSLP in 116 
keratinocytes with persistently expressed KLK5 was independent of PAR2 activity, and that 117 
inhibition of KLK5 activity with the serine protease inhibitor SFTI-G reduced cytokine production 118 
and normalised DSG1 protein expression. Furthermore, persistent KLK5 over-expression alters 119 
keratinocyte behaviour in vivo, resulting in epidermal acanthosis similar to that observed in AD skin, 120 
indicating a key role for KLK5 in AD pathology.  121 
 122 
 123 
 124 
 125 
 126 
 127 
 128 
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Materials and Methods 129 
Skin biopsies and haematoxylin and eosin staining (H&E) 130 
Skin biopsies were taken from non-lesional and lesional skin from five AD patients. Five age-131 
matched healthy donors were also obtained. This study was approved by the local ethics committee 132 
(LREC number 05/Q0508/106). Skin samples were formalin fixed paraffin embedded, and H&E 133 
staining was performed on 6 µm thickness paraffin skin sections using standard histochemistry 134 
techniques.  135 
 136 
Immunostaining and protein quantification  137 
Immunofluorescence and immunohistochemistry staining were carried out on frozen or paraffin 138 
embedded tissue sections using a purified anti-KLK5 mouse polyclonal antibody in 1:500 dilutions 139 
(Novus Biologicals, Abingdon, UK), or an anti-DSG1 mouse monoclonal antibody recognizing N-140 
terminal extracellular domain (clone P124) in 1:100 dilutions (2B Scientific Ltd, Upper Heyford, 141 
UK), or an anti-FLG monoclonal antibody in 1:100 dilutions (Leica biosystems, Newcastle, UK), or 142 
an anti-involucrin mouse monoclonal antibody in 1:1000 (Sigma, Dorset, UK) or an anti-keratin 10 143 
mouse monoclonal antibody (clone number LHP2, a gift from Royal London Hospital, UK). 144 
MolecularProbes secondary antibodies conjugated with florescence dye were obtained from Life 145 
Technologies (Paisley, UK). The detection of immunohistochemistry used biotinylated secondary 146 
antibodies and DAB substrate kit for peroxidase (Vector laboratories, Peterborough, UK). The 147 
staining procedures were as described by Di et al17, and negative controls were performed in each 148 
staining with the secondary antibody alone.  149 
The quantification of protein expression and activity in the epidermis was performed based on the 150 
staining intensity using software Image-Pro Plus v6.0 (Media Cybernetics, Cambridge, UK). Briefly 151 
images of three non-overlapped but adjacent regions in each section were recorded and saved 152 
digitally. The epidermis in each image was then highlighted as an area of interest (AOI) and the 153 
defined positive staining threshold was applied to the AOIs. The optical counts of positive staining 154 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 7 
within AOIs were automatically counted based on the defined threshold and the expression or 155 
activity in each AOI was calculated as mean staining intensity /area. 156 
 157 
Primary keratinocyte and keratinocyte cell line culture  158 
Primary keratinocytes and fibroblasts were isolated from skin biopsies by incubation with 0.25% 159 
trypsin-EDTA (Life Technologies, Paisley, UK) 3 hours for keratinocytes and Serva 50 U/ml 160 
collagenase NB6 (Universal Biologicals, Cambridge, UK) 2 hours for fibroblasts. Isolated primary 161 
keratinocytes were then co-cultured with lethally irradiated 3T3 mouse fibroblasts and grown in 162 
keratinocyte culture media. The media contained equal amount of DMEM and DMEM/Ham F12 163 
(Life Technologies, Paisley, UK) supplemented with 10% FCS (Labtech, East Sussex, UK), 100 164 
IU/ml of penicillin and 100 µg/ml of streptomycin (Life Technologies, Paisley, UK). Human 165 
keratinocyte growth supplement was then added to the media at final concentrations of 10 ng/ml of 166 
EGF (Bio-Rad AbD Serotec, Oxford, UK), 0.4 µg/ml of hydrocortisone, 5 µg/ml of transferrin, 5 167 
µg/ml of insulin, 2x10-11 M of liothyronine and 1x10-10 M of cholera toxin (Sigma, Dorset, UK). 168 
Ntert18, a keratinocyte cell line was cultured in the same keratinocyte media. Fibroblasts were 169 
cultured in DMEM supplemented with 10% FCS, 100 IU/ml of penicillin and 100 µg/ml of 170 
streptomycin. 171 
 172 
Ex-vivo dermatitis model and immunofluorescent staining 173 
Skin from female breast tissue, obtained with informed consent and ethical approval (LREC 174 
07/Q1704/59) following mastectomy was used as an ex vivo dermatitis model.  The skin, which was 175 
surplus to histopathology requirement, was placed in ice cold PBS immediately following removal 176 
and stored on ice for a maximum of 2 hours, then placed into a 60 mm petri dish and the epidermal 177 
surface carefully blotted dry.  Rubber O-rings with a diameter of 8 mm were sealed on to the skin 178 
using soft paraffin wax to create wells; care was taken to ensure that paraffin wax was applied only 179 
to the area where the O-ring made contact with the skin in order to avoid altering the permeability 180 
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of the skin or the protease activity within the epidermis.  To prevent the skin from drying out during 181 
the incubation period, the remaining space within the petri dish was filled with DMEM, containing 182 
10% FCS, at a depth of approximately 2 mm, ensuring no medium touched the epidermal surface of 183 
the skin.  Irritant substances and appropriate vehicle controls were applied carefully to separate 184 
wells (50 µl solution each) and the skin incubated at 37°C with 5% CO2 for the required length of 185 
time.  Following incubation, the entire irritant and vehicle control solutions were aspirated off the 186 
epidermis and 6 mm punch biopsies were taken from the treated sites of the skin sample (without 187 
removing the rubber O-rings) using sterile biopsy punches.  A fresh biopsy punch was used for each 188 
treatment to avoid cross-contamination, and the biopsy was removed from within the rubber O-ring 189 
using forceps to ensure only treated skin was extracted. The biopsied tissue was placed in a 1.5 ml 190 
eppendorf tube and snap frozen in liquid nitrogen.  Samples were stored at -80oC until further 191 
investigations. 192 
Following removal of skin biopsies from -80°C storage and embedding in Tissue-Tek® optimal 193 
cutting temperature medium (OCT) (Sakura Finetek, Thatchem, UK), 8 µm tissue sections were cut 194 
on a cryostat, allowed to dry onto poly-L-lysine coated glass slides, then fixed for 10 minutes in ice 195 
cold acetone at -20°C. Slides were washed with TBS, blocked for 30 minutes with blocking buffer 196 
followed by incubation with primary antibody in TBS overnight at 4°C. Slides were washed for 3 x 197 
5 minutes in TBS, subsequently incubated with secondary antibody for 1 hour in the dark, then 198 
washed in TBS for 3 x 5 minutes and, where necessary, counterstained by incubation with DAPI for 199 
10 minutes, followed by a final wash of 3 x 5 minutes in TBS.  Coverslips were attached using 200 
Mowiol and the samples then visualised by fluorescence microscopy (Axioskop 2 MOT, Zeiss).  201 
Slides were magnified at 100x and 400x and images digitally recorded (Axiocam, Zeiss). Slides 202 
stained in the absence of primary antibody were used to set the exposure levels to reduce 203 
background staining.  Images were analysed using ImageJ v1.46 software, with 10 vertical regions 204 
of interest (ROI’s) from outer to inner surface of the epidermis selected from 1 field of view from 3 205 
consecutive sections for each sample and the contribution from each layer along this measurement 206 
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was recorded. The 10 measured ROIs were normalised to 100% and the mean pixel intensity 207 
obtained for every 5% of the depth (i.e. from outer to inner surface) of the epidermis. The minimum 208 
average pixel intensity for a 5% section in the PBS sample was set at 1 and all other readings for the 209 
sample set calculated relative to this value. 210 
 211 
Construction of lentiviral vectors and transduction of keratinocytes 212 
Human KLK5 cDNA was cloned into the pCCL lentiviral vector containing upstream spleen focus-213 
forming virus (SFFV) promoter and downstream enhanced green fluorescent protein (eGFP) 214 
reporter gene linked to KLK5 via an internal ribosomal entry sequence from the endomyocarditis 215 
virus. The vector encoding eGFP alone was used as negative control. Lentiviruses were produced 216 
by co-transfecting 293T cells. Infectious lentiviruses were harvested 48 and 72 hours post-217 
transfection, and the culture supernatants were concentrated by ultracentrifugation. The lentivirus 218 
concentration were titrated by viral copy number using qPCR and flow cytometry and the titres of 219 
eGFP viral vector and KLK5/eGFP viral vector were 8x108  and 4x108  TU/ml, respectively.  220 
Human primary keratinocytes and cell line Ntert were transduced by one round of exposure to 221 
eGFP or KLK5/eGFP vectors at an MOI of 10. Transduced cells were subcultured for further 222 
experiments.  223 
 224 
Intracellular calcium mobilization assay 225 
Measurement of intracellular calcium mobilization was performed using FluoForte Calcium Assay 226 
kit (Enzo Life Sciences, Exeter, UK). Mobilization of intracellular calcium was detected utilizing a 227 
fluorogenic calcium-binding dye. Keratinocytes were plated in 96-well plates at the density of 1 × 228 
104 cells per well. After 24 hours, the growth medium was removed and 100µl of dye-loading 229 
solution was added. The cells were further incubated with the dye-loading solution for 45 min at 230 
37oC and then 15 minutes at room temperature. The cells were then inoculated with 100 µM of 231 
PAR2 activating peptide SLIGKV-NH2, (Bachem, Cambridge Bioscience, Cambridge, UK), and 232 
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intracellular calcium signal was recorded via real-time monitoring of fluorescence intensity at 233 
excitation of 530 nm and emission of 570 nm using the microplate reader FLUOstar OPTIMA, 234 
(BMG, Lutterworth, UK). Intracellular calcium mobilization was calculated as changes of 235 
fluorescence intensity in relative fluorescence units (RFU) and the mobilisation curves were 236 
generated by RFU values plotted against the time. 237 
 238 
Western blotting 239 
Cells were suspended in a cooled lysis buffer composed of 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 240 
5 mM EDTA, cocktail protease inhibitors and 1 mM PMSF. Samples were incubated for 15 minutes 241 
at 4oC and then were centrifuged at 12,000 RPM for 15 minutes. The total protein concentration in 242 
the supernatant of lysed sample was determined by Bio-Rad protein assay Kit (Bio-Rad, 243 
Hertfordshire, UK). Samples were further diluted 5 times in 0.5 mM Tris-HCl pH 6.8 sample buffer 244 
containing 100 mM DTT, 10% SDS, 30% glycerol, 0.001% bromphenol blue. Equal amounts of 245 
total protein were loaded in SDS-PAGE. After electrophoresis, proteins were transferred to PVDF 246 
membranes and incubated with primary antibody overnight. The following day, membranes were 247 
incubated with secondary antibody conjugated with horseradish peroxidase (Sigma, Poole, UK), 248 
and signals were detected using the ECL Prime system (GE Healthcare, Bucks, UK). Ponceau red 249 
(Sigma-Aldrich, Poole, UK) staining was used as loading control for culture supernatants.  250 
 251 
In situ zymography and casein gel zymography  252 
In situ zymography assay using casein-derived substrate measured the total protease activity in the 253 
skin. Briefly, the frozen skin sections were rinsed with PBS containing 0.1% Triton X-100 (Sigma-254 
Aldrich, Poole, UK) and incubated at 37°C with 10 µg/ml casein conjugated with  BODIPY TR-X 255 
(Life Technologies, Paisley, UK) in the buffer containing 10 mM Tris-HCl, pH7.8 in a humid 256 
chamber for two hours,. The fluorescent intensity was detected under a fluorescence microscope 257 
and quantified using Image-Pro.  258 
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Casein gel zymography was used for cells that were cultured in keratinocyte culture media without 259 
FCS for 48 hours. The culture media were then collected and concentrated using Amicon 260 
centrifugal filter devices (Millipore, Watford, UK). Samples were re-dissolved in non-reducing 261 
Novex® Tris-Glycine SDS sample buffer (Life Technologies, Paisley, UK) and separated on 12% 262 
polyacrylamide gels copolymerized with casein substrate (Life Technologies, Paisley, UK). After 263 
electrophoresis, the gels were soaked in renaturing buffer containing 50 mM Tris, pH 8 and 2.5% 264 
Triton X-100 for 1 hour. The gels were then incubated in developing buffer containing 50 mM Tris, 265 
pH 8 (Life Technologies, Paisley, UK) at 37°C overnight. Casein degrading activity was visualized 266 
when the gels were stained with 1% Coomassie Brilliant blue (Sigma-Aldrich, Poole, UK).  267 
 268 
Human cytokine antibody array 269 
The cytokines in culture media collected from the different cell lines were assessed using The 270 
Human Cytokine Antibody Array Panel A kit (R&D System, Oxfordshire, UK) according to the 271 
manufactory’s instruction. A total number of 36 cytokines were measured and the intensities of the 272 
blots were quantified by densitometry. As each reference or target protein was blotted in duplicate, 273 
mean pixel density from duplicate blots was calculated and normalised by reference blots. 274 
 275 
RT-PCR for IL-8 276 
Following RNA extraction using the RNeasy® Plus Mini Kit (Qiagen), a second genomic DNA 277 
elimination step was employed to prevent genomic DNA contamination, and cDNA was then 278 
synthesised using the RT2 first strand kit (SABiocience). Quantitative PCR was performed in 279 
duplicate wells for each time point using a 7900HT Fast Real-Time PCR System (Applied 280 
Biosystems, CA, USA) and the data collected using SDS 2.4 software (Applied Biosystems, CA, 281 
USA).  The PCR protocol consisted of an initial cDNA denaturation at 95°C for 10 min, followed 282 
by 35 cycles of denaturation at 95°C for 15 seconds and annealing and data collection at 60°C for 283 
60 seconds.  ∆CT values were calculated using the Ct value for the housekeeping gene 26S and 284 
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analysis of fold change in gene regulation was performed using automated Microsoft Excel analysis 285 
tools from SABioscience. 286 
 287 
Enzyme linked immunosorbent assay (ELISA) 288 
Cells were seeded in 24 well plates and cultured until confluence, then cultured in serum free media 289 
for 48 hours before culture media were collected and concentrated using Amicon centrifugal filter 290 
devices (Millipore, Watford, UK). The total protein concentration was quantified using Bio-Rad 291 
protein assay kit. The level of IL-8 was measured using IL-8 ELISA kit (BD Biosciences, Oxford, 292 
UK). TSLP and IL-10 were quantified using ELISA kits from eBioscience (eBioscience, Hatfield, 293 
UK). All sample reads were normalized to the total protein concentration. 294 
 295 
Bio-engineered skin sheet and grafting onto immunodeficient mice  296 
The methods of generating bio-engineered skin sheet and grafting to mice were as described by Di 297 
et al19. Briefly, primary human keratinocytes were seeded on the top of a fibrin matrix populated 298 
with primary human fibroblasts. After keratinocytes reached confluence, the bioengineered skin 299 
constructs were grafted onto the dorsum of 6 weeks old female immunodeficient mice (NMRI 300 
strain, Charles River, UK). 8 weeks after grafting, skin samples from grafts were taken post-mortem 301 
and formalin fixed and paraffin-embedded or OCT-embedded. H&E staining and immunostaining 302 
for KLK5, FLG and DSG1, and zymographics were performed on these tissues.  303 
 304 
 305 
 306 
 307 
 308 
 309 
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Results  310 
Increased expression and activity of KLK5 in AD skin 311 
Skin biopsies taken from lesional and non-lesional skin in five children with AD were examined for 312 
epidermal morphology and KLK5 expression. Five age-matched normal donor skin biopsies were 313 
used as controls. Compared to normal skin, AD lesional skin exhibited epidermal changes including 314 
acanthosis, spongiosis, parakeratosis and elongated rete ridges. Non-lesional skin also showed 315 
histopathological characteristics consistent with the disease, but far less prominent than those 316 
observed in lesional skin (Figure 1A. a-c). The expression of KLK5, as detected by 317 
immunostaining, was localised in the cornified layer in normal skin, whereas in AD skin, especially 318 
in the lesional skin, KLK5 was present in the granular layer and upper stratum spinosum with high 319 
staining intensity (Figure 1A. d-f and Supplementary materials, Figure S1). Quantification of 320 
KLK5 based on mean optical staining intensity/area further demonstrated significant increased 321 
expression of KLK5 in both lesional and non-lesional AD skin, compared to the normal skin 322 
(p<0.05) (Figure 1B). As DSG1 is the proteolytic substrate of KLK5, and FLG can be degraded by 323 
elastase 2 which is a serine protease activated by KLK5 in the skin20, DSG1 and FLG expressions 324 
were also examined by immunostaining. Both FLG and DSG1 expression were significantly 325 
reduced in lesional skin of AD (p<0.05) (Figure 1A. g-i & j-l, Figure 1B). The protease activity in 326 
the skin were further examined by in situ staining, and results showed a similar location and 327 
staining pattern to KLK5 expression with more diffuse and enhanced fluoresecence intensity in the 328 
AD skin (Figure 1A. m-o, Figure 1B and Supplementary materials, Figure S2). Although the 329 
caseinolytic serine protease assay detects total protease activity, as KLK5 is a major serine protease 330 
in the skin2 and the protease activity closely matched the extent and distribution of KLK5 protein 331 
expression, it is likely that KLK5 is a significant contributor to the increased activity of serine 332 
protease observed in the AD skin.  333 
 334 
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Transient up-regulation of KLK5 stimulated PAR2, but persistant activated KLK5 335 
desensitised PAR2  336 
The expression of the KLK5 targeted molecule PAR2 was further examined in the donor skin (n=5) 337 
and AD non-lesional and lesional skin by immunostaining. No significant changes in PAR2 338 
expression was noted in lesional, non-lesional AD skin and normal donor skin (p>0.05) (Figure 1A. 339 
p-r, Figure 1B), although there was a fluctuation of PAR2 expression level among individuals. 340 
This result suggests that up-regulated KLK5 does not modify PAR2 in AD skin. Considering that 341 
the up-regulation of KLK5 was likely to be chronic and persistant in AD skin, we speculated that 342 
the response of PAR2 to KLK5 might differ between AD skin and skin with transient KLK5 up-343 
regulation. To determine this, the influence of transiently increased KLK5 on PAR2 was tested 344 
using an ex-vivo irritant dermatological model in which irritants were applied onto normal skin 345 
cultured in vitro. Following  the application of croton oil or SDS or acetone for 30 minutes on the 346 
ex-vivo skin model, increased epidermal expression of KLK5 and PAR2 were detected in the 347 
epidermis (Figure 2. a). Quantification using image analysis confirmed significantly higher 348 
expression of both KLK5 and PAR2 across all layers of the epidermis (Figure 2. b-e).  349 
The effect of persistently increased KLK5 on PAR2 was tested in the keratinocyte cell line Ntert 350 
(KLK5-Ntert) or primary keratinocytes (KLK5-pKC) ectopically over-expressing KLK5. Cells 351 
transduced with eGFP vector alone were used as control (GFP-Ntert or GFP-pKC). The 352 
transduction efficiency in both KLK5 transduced cells and GFP transduced cells was nearly 60% as 353 
determined by eGFP expression. Overexpression of KLK5 in KLK5-transduced cells and culture 354 
media was confirmed by western blotting (Figure 3. a&c). The activity of KLK5 was further 355 
assessed by zymography. Active KLK5 was detected in the culture media collected from KLK5 356 
transduced cell culture (Figure 3. d), but not in cell lysates (Figure3. b). KLK5 is synthesized as 357 
inactive pre-pro-KLK5 (precursor or zymogene) which is then translocated into the endoplasmic 358 
reticulum in cells (see review by Debela M et al)21. Following the removal of the signal peptide 359 
(~30 amino acids), the pre-pro-KLK5 becomes pro-KLK5 that is secreted into the extracellular 360 
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space and subsequently becomes activated upon release of its 37 amino acids propeptide from the 361 
N-terminus of KLK5. Thus, the KLK5 extracted from the cells would not contain the final activated 362 
KLK5 and it is not surprising that there was no positive digested band detected in zymography 363 
loaded with cell lysates. In contrast, a digested band was seen in zympgraphy loaded with culture 364 
medium from cells over expressing KLK5/eGFP as a result of the culture medium containing the 365 
active form of KLK5. Although a ~70kDa band was present on both western blotting and 366 
zymography, the intensity of the protein band remained unchanged among cell lysates from 367 
untransduced cells, cells transduced with GFP alone and KLK5/GFP, therefore this was considered 368 
to represent a nonspecific protein, but having a proteolytic activity on casein-derived substrate.  369 
The durability of KLK5 expression in both KLK5-Ntert and KLK5-pKC was assessed following 370 
propagation of transduced cells and there was no decline in KLK5 expression over this time as 371 
determined by eGFP expression, indicating persistent KLK5 expression in the KLK5-cell model 372 
(Supplementary materials, Figure S3). As a previous study showed that PAR2 was mainly 373 
expressed in differentiated keratinocytes, the Ntert cell line was checked for differentiation markers 374 
keratin 10 and involucrin and results showed positive expression for both proteins (Supplementary 375 
materials, Figure S4). The activity of PAR2 and a KLK5 down-stream target was then examined 376 
in untransfected Ntert (UT-Ntert), GFP-Ntert and KLK5-Ntert by a PAR2-dependent calcium 377 
mobilisation assay. Mobilisation of calcium was observed in the untransfected keratinocytes after 378 
addition of a PAR2 agonist (AP), and similarly following addition of recombinant KLK5 (rKLK5), 379 
albeit slightly later than that induced by AP (Figure 4. a), confirming that KLK5 was able to 380 
activate PAR2. In contrast, a decline in calcium mobilisation was detected in KLK5-Ntert cells 381 
compared to that in GFP-Ntert (Figure 4. b). Thus, a different PAR2 dependent calcium 382 
mobilisation response was observed in cells with persistent expression of KLK5 versus cells with 383 
transient rKLK5 stimulation.  384 
PAR2, like many other receptors, can be desensitized if continuously or repeatly exposed to its 385 
agonist22,23, and these results suggest that persistent over-expression of KLK5 could desensitise the 386 
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PAR2 receptor resulting in a lower response of PAR2 to its agonist AP. Since PAR2 desensitisation 387 
can be reversed by removal of PAR2 activators, we looked at calcium mobilisation when KLK5-388 
Ntert cells were treated with the serine protease inhibitor SFTI-G, an analogue derived from the 389 
naturally occurring substance sunflower trypsin inhibitor 124.  Following treatment with 100µM 390 
SFTI-G overnight, the PAR2 dependent calcium mobilisation in KLK5-Ntert cells recovered to 391 
levels similar to that in GFP-Ntert and untransfected keratinocytes (Figure 4. c).  392 
 393 
Persistently activated KLK5 induced cytokine expression/secretion despite PAR2 394 
desensitisation   395 
Activated PAR2 induced pro-inflammatory cytokine elevation and secretion, including of IL-8, has 396 
been reported25. In the ex-vivo irritant dermatological skin model, increased IL-8 mRNA expression 397 
was detected by RT-PCR within 12 hours following exposure to SDS and to a lesser extent at 12 398 
hours following application of croton oil (Figure 5. a). In the KLK5-pKC cells with persistent 399 
KLK5 expression, IL-8 protein, measured by cytokine antibody array, was also increased (Figure 400 
5.b&c). In addition, IL-10 was elevated in KLK5-pKC cells (Figure 5. b&c), but other cytokines 401 
including IL-1, IL-4, IL-6 and IFN-gamma were not (Supplementary materials, Table S1). TSLP, 402 
a prominent pro-inflammatory cytokine in AD skin also showed increased expression in KLK5-403 
pKC cells as measured by ELISA (Figure 5. c). However, increased IL-10 and TSLP were not 404 
detected in cells transiently challenged with rKLK5 (data not shown).  405 
 406 
Inhibition of persistent KLK5 activity reversed KLK5 effects on DSG1 and cytokine 407 
production  408 
To examine the downstream effects of inhibition of persistently raised KLK5 activity, primary 409 
keratinocytes transduced with KLK5 (KLK5-pKC) or eGFP (GFP-pKC) were cultured in serum 410 
free media inoculated with 100 µM of serine protease inhibitor SFTI-G for twenty-four hours. 411 
Although the level of secreted KLK5 in culture media, as determined by western blot, remained 412 
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elevated in the KLK5-pKC cells 24 hours post SFTI-G treatment, the expression of full length 413 
DSG1 was restored in treated KLK5-cells compared to untreated cells, whereas there was no 414 
significant change in the level of DSG1 in GFP-pKC cells before (-) and after SFTI-G (+) 415 
treatment, indicating the suppression of KLK5 activity by SFTI-G in the KLK-5 culture (Figure 6. 416 
a). It was noticed that in KLK5-pKC cells, there was no DSG1 detected. The DSG1 antibody used 417 
in the study was a monoclonal antibody (clone P124) recognizing the N-terminal extracellular 418 
domain of DSG1 and full length DSG1. Primary keratinocytes were used for untreated as well as 419 
treated experiments, and treated cells showed a DSG1 band. Therefore, no DSG1 band in KLK5-420 
pKC cells without SFTI-G treatment was most likely due to DSG1 levels being to too low to be 421 
detected and/or the antibody does not recognize the cytoplasm domain of DSG1 alone following the 422 
cleavage of the extracellular domain by over-expressed/activated KLK5.  Cytokines IL-8, IL-10 and 423 
TSLP were also significantly reduced in SFTI-G treated KLK5-pKC cells, compared to untreated 424 
KLK5-pKC cells, and these changes were not observed in treated or untreated GFP-cells as 425 
confirmed by both cytokine antibody array and ELISA (Figure 5.b, 6.b&c, Supplementary 426 
materials, Table S1).  427 
 428 
Keratinocytes with persistent activated KLK5 exhibit an AD-like epidermal architecture 429 
To examine the influence of persistently up-regulated KLK5 activity on epidermal architecture in 430 
vivo, primary keratinocytes from the non-lesional skin in a patient with AD (AD-pKC), or primary 431 
normal keratinocytes ectopically over-expressing KLK5 (KLK5-pKC) or GFP (GFP-pKC) were 432 
cultured in vitro as bio-engineered skin and grafted onto immuno-deficient mice. 8 weeks post-433 
grafting, the skin from the grafted area was harvested. Grafts generated from KLK5-pKCs and AD-434 
pKC showed AD-like morphology, with acanthosis, mild parakeratosis and enlarged intercellular 435 
spaces compared to the GFP-pKC graft (Figure 7. a-c). Increased expression of KLK5 and protease 436 
activity and decreased DSG1 were observed in both KLK5-pKC and AD-pKC grafts compared to 437 
GFP-cell graft (Figure 7. d-l), which were analogous to findings in AD skin. Altered FLG 438 
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expression was also detected in KLK5-pKC and AD-pKC grafts, it was more evident in the upper 439 
stratum spinosum similar to that seen in the AD skin (Figure 7. m-o and Figure 1A. h&i). As the 440 
FLG antibody used for the study only detects FLG produced from human cells, the mouse-human 441 
skin boundary was easily visible in the FLG stained skin, indicating that the keratinocytes within 442 
the grafts were of human origin (Figure 7. g-i). In addition, the mouse-human skin boundary 443 
images showed an increased thickness of mouse epidermis (acanthosis) next to the grafts generated 444 
by KLK5-pKC and AD-pKC, but not by the GFP-pKC, which may have resulted from a paracrine 445 
effect of activated KLK5 secreted from these grafts. 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
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Discussion  463 
Up regulated KLK5 together with skin barrier defects in AD has been reported in previous 464 
studies10,11,26, which have shown that both genetic and environmental factors can cause aberrant 465 
KLK5 activity. Indeed, as AD shares a number of clinical features with NS, it has been speculated 466 
that AD might also share some pathological mechanisms of dysfunctional skin barrier with NS27,28. 467 
Genome-wide association studies have shown several single nucleotide polymorphisms (SNPs) in 468 
SPINK5 associated with AD, in particular Glu420Lys28 and functional investigations have further 469 
confirmed that Glu420Lys SNP alters SPINK5 encoded protein LEKTI proteolytic activation and 470 
results in dysregulation of  proteases including the KLKs29.  Environmental factors that disrupt the 471 
skin barrier, including irritants and infection, and trigger KLK5 up-regulation have also been 472 
reported30. In this study, we have demonstrated that the irritants croton oil and SDS increase KLK5 473 
and PAR2 expression, but that transient KLK5 expression seems to have different effects on PAR2 474 
expression/activity than that observed with persistent KLK5 expression.  475 
KLK5 activation of PAR2 has been demonstrated previously31 and we also showed rKLK5 476 
activated PAR2 in this study using an intracellular calcium mobilization fluorescence assay. The 477 
fluorescence peak induced by rKLK5 was, however, delayed 40-50 seconds compared to the peak 478 
induced by the PAR2 agonist (AP). This difference in peak time was likely to be due to the tethered 479 
ligand mechanism with regards to maximum rate of PAR2 activation by KLK5. Oikonomopoulou 480 
and colleagues31 have reported that KLK5 activation of PAR2 is a two-step process involving 481 
cleavage and tethered ligand binding to the PAR2 receptor, whereas a one-step process is involved 482 
in the PAR2 agonist directly binding to the receptor. 483 
The signalling pathway of KLK5-PAR2-NFκB-cytokines has been recognised for more than a 484 
decade32,33, but most studies have been carried out in models with transient exposure to exogenous 485 
rKLK531. PAR2 can exhibit desensitization due to continuous or repeated stimulation by its agonist, 486 
leading to reduced responsiveness34. AD is a chronic skin condition, and up-regulated KLK5 487 
activity in affected skin is most likely to be persistent than transient. However, the examination of 488 
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PAR2 activity in skin in situ is technically difficult. Currently, the activity of PAR2 is assessed by 489 
intra-cellular calcium mobilization in live cells following stimulation/inhibition with its 490 
agonist/antagonist. Tissues from AD skin or murine AD models are generally fixed/embedded or 491 
snap frozen, and thus are not suitable for use in the calcium mobilization assay. There is an indirect 492 
way to check PAR2 activity by examination of PAR receptor internalization, e.g. by tracking GFP-493 
tagged PAR2 fusion protein trafficking35 or by analysing the distribution of activated (cytoplasmic) 494 
and unactivated (cell membrane) PAR2 receptor36, but these also require cell-culture models rather 495 
than skin tissue. However, although the desensitisation of PAR2 in the skin in situ cannot be 496 
measured directly, previous work by Moniaga and colleagues37 supports our view that PAR2 is 497 
desensitised in AD-like skin lesions. In their study37, a PAR2 agonist could up-regulate TLSP in 498 
murine keratinocytes following transient (one-off) stimulation, but only a marginal increase of 499 
TSLP production was noted in the skin of flaky tail mice following repeated topical application of 500 
dust mite for 7 weeks; this discrepancy of TLSP production between transient stimulation in cell 501 
culture and repeated challenge in mouse skin was probably because the repeated challenge caused 502 
PAR2 desensitisation, resulting in low PAR2 activity. Related to this, an in vivo study by Briot and 503 
colleagues showed that TLSP production was independent of PAR2 activation and that PAR2 was 504 
not central to the production of the skin inflammation when there was persistent KLK5 activity38.  505 
In mice with double knockout of SPINK5-/- and PAR2-/- and high KLK activity, the deletion of 506 
PAR2 in the adult double knockout-grafted skin did not result in the reduction of TLSP and did not 507 
suppress the skin inflammation38. This result suggests that the inflammatory skin in Netherton 508 
syndrome and AD is not solely caused by PAR2 activation.  509 
Based on our observations in the AD skin with persistent KLK5 overexpression and the ex-vivo 510 
irritant dermatological skin model mimicking a transiently increased KLK, we demonstrated that 511 
PAR2 had a higher response to transient KLK5 stimulation, but had a weak response to persistent 512 
KLK5 stimulation. Interestingly, despite the low activity of PAR2 in cells overexpressing KLK5, 513 
these cells up-regulated and secreted pro-inflammatory and Th2-polarizing cytokines, including IL-514 
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8, IL-10 and TSLP, indicating that persistent KLK5 induced IL-8, IL-10 and TSLP. The exact 515 
pathway of persistent KLK5 expression/activity induced IL8, IL10 and TLSP secretion in KLK5-516 
pKC remains unclear, and further investigations will be required to elucidate this. The keratinocyte-517 
based nature of our KLK5 over-expressing model, which lacks immune cells, meant that it was not 518 
possible to investigate cytokine secretion from immune cells following KLK5 activation, which 519 
may explain why our cytokine antibody array data did not show elevation of other 520 
cytokines/chemokines reported in AD patients (such as IL-6, IL-4, GM-CSF, IL-1 and TNFα).  521 
The influence of activated KLK5 on epidermal architecture in the in vivo human:murine chimeric 522 
skin graft model, which showed AD-like skin architecture in grafts generated using cells over-523 
expressing KLK5, further indicated that KLK5 plays a key role in this process. Similar observations 524 
have also been detected using a transgenic mouse model over-expressing KLK539. Furthermore, as 525 
the human:murine chimeric skin graft model was immunodeficient and maintained in specific 526 
pathogen-free environment, our results suggest that the AD-like histopathological features and 527 
abnormal barrier protein expression in the epidermis generated by AD-cells and KLK5-pKC cells 528 
were a specific consequence of persistent up-regulation of KLK5 in the keratinocytes. 529 
Our study also suggests that increased KLK5 in AD skin should not simply be viewed as a 530 
‘biomarker’ in this skin disorder, but as a protease which has significant functional impact in this 531 
condition. In AD patients, environmental factors can trigger the cytokine cascade and stimulate a 532 
Th2-skewed inflammatory infiltrate through the initial defective skin barrier, resulting in 533 
susceptibility to allergy or ‘atopy’ (“outside-inside” aetiological mechanism)16,40. The induced 534 
inflammatory response further compromises barrier function, causing keratinocyte damage and 535 
inducing upregulation of certain molecules, such as KLK5. The initial damage secondary to 536 
increased KLK5 forms a vicious cycle of inflammation-induced barrier impairment in AD (outside-537 
inside-outside)16.  538 
Amongst the currently known inhibitors of kallikreins41-43, the naturally occurring cyclic peptide 539 
SFTI has been extensively investigated due to it being amenable to chemical manipulation which 540 
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has allowed for the creation of synthetic variants44-46. We used the analogue SFTI-G derived from 541 
SFTI24 to control KLK5 activity and our in vitro results showed a normalised DSG1 expression, 542 
depletion of depressed PAR2 dependent calcium mobilisation and reduction of IL-8, IL-10 and 543 
TSLP. Thus, reducing KLK5 activity could offer a therapeutic option for the treatment of AD, 544 
where control of higher KLK5 activity might help to reverse (at least part of) the AD phenotype in 545 
patients with this disorder. 546 
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Legends 
Figure 1.   Skin morphology and protein expression in AD   
A: Skin sections from normal donor (n=5) and AD skin (n=5) were examined by H&E (a-c), 
immunostaining (d-l & p-r), and in situ zymography (m-o). Green/brown colour represents 
protein expression or protease activity. Nuclei were stained in blue colour. Scale bar = 50 µm. 
 B: Quantification of staining intensity (n=3 per sample) was measured by mean staining 
intensity/area using ImagePro.  
 
Figure 2. Increased KLK5 and PAR2 expression in ex-vivo dermatitis skin model 
Immunofluorescence staining of epidermal KLK5 and PAR2 following application of 3% croton 
oil and 5% SDS compared with acetone-treated and PBS-treated skin. Quantification of relative 
KLK5 (b,d) and PAR2 (c,e) expression from stratum corneum to basal layer (0%-100% depth 
respectively).  KLK5 (n=9, n=7), PAR2 (n=7, n=6) for 3% croton oil and 5% SDS respectively. 
 
Figure 3.   Characterisation of keratinocyte over expressing KLK5 
The expression and activity of KLK5 in cell lysate (a,b) and culture media (c,d) from the cells 
transfected with KLK5 gene were examined by Western blot (left panel) and gel zymography 
(right panel). β-actin were used as loading controls. UT = untransduced cells; eGFP = cells 
transduced with eGFP alone vector; KLK5 = cells transduced with KLK5/eGFP vector and 
rKLK = activated recombinant KLK5 protein (where rKLK was added directly to the gel as a 
positive zymography control).  
 
Figure 4. PAR2-dependent calcium mobilisation in keratinocytes  
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PAR2-dependent calcium mobilisation was measured in untransfected Ntert cells challenged 
with AP or rKLK5 (a); cells transfected with GFP or KLK5 challenged with AP (b); and cells 
transfected with GFP or KLK5, treated with SFTI-G and then challenged with AP (c). PBS was 
used as negative control.  
 
Figure 5.  Cytokine expression in keratinocytes  
Cytokine levels were measured in the ex-vivo skin model with transiently up-regulated KLK5 
using RT-PCR for IL8 (a); KLK5-pKC cells with persistent KLK5 expression using antibody 
array blots (b). The IL-8 and IL-10 levels detected by cytokine antibody array and quantified by 
mean pixel density, and TSLP level measured by ELISA are shown in the bar chart (c).  Data in 
(a) are shown relative to PBS-treated skin. 
 
Figure 6. The inhibition of KLK5 by serine protease inhibitor SFTI-G 
Primary keratinocytes transduced with GFP or KLK5 gene were treated with 100µM of SFTI-G 
overnight. KLK5 in culture media and DSG1 in cell lysates were measured by Western blot (a). 
Cytokine secretions in the culture media following SFTI-G treatment were measured by 
cytockine antibody array (b) and confirmed by ELISA (c).  The symbol * is representative of 
statistical significance (p<0.05) and NS stands for non-significance.  
 
Figure 7.   Persistent KLK5 activity induced AD-like skin changes 
A: Skin graft sections from human:murine skin graft mice were examined for morphology by 
H&E (a-c),  KLK5 (d-f) expression by immunohistochemistry, DSG1 (j-l) and FLG (m-o) 
expression by immunofluorescence, and protease activity (g-i) by in situ zymography. Brown 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
and green colour show protein expression/protease activity and purple and blue colour show 
stained nuclei. Scale Bar= 50 µm. 
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Supplementary materials 
 
 
Table S1. Quantification of dots by densitometry for cytokine antibody array  
 
 
Coordinate 
of the plate 
Target/control 
Mean pixel density 
GFP-pKC KLK5-pKC 
SFTI  (-) SFTI (+) SFTI (-) SFTI (+) 
A1,A2 Reference spot 17896 17221 17701 17193 
A3,A4 C5/C5a 232 294 245 302 
A5,A6 CD40 ligand 216 259 241 226 
A7,A8 G-CSF 308 299 327 302 
A9,A10 GM-CSF 341 367 319 298 
A11,A12 GRO-alpha 18958 19020 19110 19212 
A13,A14 I-309 327 381 338 306 
A15,A16 sICAM-1 404 394 420 441 
A17,A18 IFN-gamma 336 385 312 397 
A19,A20 Reference spot  16350 16361 16222 16119 
B3,B4 IL-1a 188 226 209 198 
B5,B6 IL-1b 217 275 232 202 
B7,B8 IL-1ra 15933 15659 15899 16021 
B9,B10 IL-2 297 310 268 289 
B11,B12 IL-4 322 338 301 297 
B13,B14 IL-5 275 311 291 298 
B15,B16 IL-6 397 344 380 393 
B17,B18 IL-8 15922 15273 22598 16276 
C3,C4 IL-10 224 243 8236 268 
C5,C6 IL-12 p70 313 289 326 301 
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C7,C8 IL-13 406 484 415 461 
C9,C10 IL-16 359 331 360 314 
C11,C12 IL-17 448 429 465 438 
C13,C14 IL-17E 385 375 397 408 
C15,C16 IL-23 535 521 519 569 
C17,C18 IL-27 449 425 456 406 
D3,D4 IL-32a 398 331 386 350 
D5,D6 IP-10 421 452 409 398 
D7,D8 ITAC 415 429 406 466 
D9,D10 MCP-1 399 411 394 429 
D11,D12 MIF 12868 12525 13310 12806 
D13,D14 MIP-1a 275 310 298 322 
D15,D16 MIP-1b 393 404 415 438 
D17,D18 Serpin E1 18256 18010 18166 18125 
E1,E2 Reference spot 17510 17725 17566 17621 
E3,E4 RANTES 435 509 466 428 
E5,E6 SDF-1 449 399 425 462 
E7,E8 TNF-alpha 398 439 412 402 
E9,E10 sTERM-1 421 461 435 489 
E19,E20 Negative control 275 211 261 293 
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Legends 
 
Figure S1. KLK5 expression in non-lesional and lesional skin from five AD patients  
Skin sections from normal donor (n=5, control 1-5, left panel) and AD patients (n=5, patient 1-5) 
from non-lesional (middle panel) and lesional (right panel) skin were examined for KLK5 
expression using immunohistochemistry. Brown colour represents protein expression and blue 
colour shows nuclei stain. Scale bar = 100 µm. 
 
Figure S2. In situ protease activity in non-lesional and lesional skin from AD patients 
Skin sections from normal donor (n=4, control 1-4, left panel) and AD patients (n=4, patient 1-4) 
from non-lesional (middle panel) and lesional (right panel) skin were examined for total protease 
activity by in situ zymography. Green colour represents protease activity, whereas nuclei are 
stained blue. Scale bar = 50 µm. 
Figure S3. Stability of transgene KLK5 expression in keratinocytes 
 
Primary keratinocytes and Ntert keratinocyte cell line were transduced with KLK5/eGFP 
transgene and the stability of transgene in cells was assessed by GFP positive cells (GFP+) using 
flow cytometry. Primary keratinocytes were only monitored for a period of 12 days due to 
proliferative lifespan of primary cells in in vitro culture.  
 
Figure S4. Differentiation markers in Ntert keratinocytes 
Keratin 10 and involucrin expression in cell lysates from untransduced Ntert keratinocytes (UT), 
or transduced with KLK5 (KLK5) or eGFP vector alone (eGFP) were assayed by Western blot. 
Positive expressions of both proteins indicated a proportion of differentiated cells in the Ntert 
cell line.    
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